Moving Up to 7.5 mg Mounjaro: Is Now the Right Time?

The decision your prescriber is actually making at this point

If you are reading this, you have probably completed at least eight weeks on Mounjaro and are wondering whether moving up to 7.5 mg is the right call, or whether your prescriber will agree. That uncertainty is completely reasonable. The titration schedule exists precisely because tirzepatide affects appetite, digestion and blood sugar in ways that need time to stabilise at each level.

A prescriber considering this step will look at two things above everything else: how well you tolerated the previous dose, and whether your body responded to it. If nausea, vomiting or digestive discomfort is still significant at 5 mg, staying put for another four weeks is often the right answer. If you sailed through and weight loss has slowed or stalled, moving up is the logical next move. Neither scenario is a failure, the titration schedule is built to accommodate both.

It is also worth knowing that 7.5 mg is not the finish line. Mounjaro's licensed strengths run through to 15 mg, and what 7.5 mg delivers depends heavily on how your individual metabolism responds. Some people find the mid-range doses the sweet spot for tolerability and effect; others need to continue. Your prescriber will keep reviewing that at every repeat.

The NICE appraisal of tirzepatide (TA1026) is grounded in trial data showing meaningful average weight reduction across the full programme, but those results reflected the highest tolerated doses over 72 weeks, not any single step along the way. The NICE guidance on tirzepatide makes clear that treatment is reviewed against ongoing response throughout.

What changes (and what does not) when the dose goes up

The mechanism does not change. Tirzepatide still activates both the GIP and GLP-1 receptors that regulate appetite signalling and slow the rate at which your stomach empties. What typically changes is the strength of that effect: hunger suppression tends to deepen, and many people notice a further reduction in portion size and snacking without making a conscious effort.

The side-effect profile at 7.5 mg mirrors what you likely experienced at the move from 5 mg upwards, nausea, loose stools, indigestion or fatigue can return in the days after a new pen is started. For most people this settles within one to two weeks as the body adjusts. It does not mean the dose is wrong; it means the dose is new.

What does not change is the injection schedule. Mounjaro remains a once-weekly subcutaneous injection, taken on the same day each week, rotating between abdomen, thigh or upper arm. Storage requirements stay identical. And the clinical oversight requirement stays identical too: a prescriber reviews your case before every repeat order, not just at titration points. That review is where dose increases (or pauses) get confirmed.

The NHS tirzepatide medicines page covers the full side-effect picture and what to watch for at any dose; it is the clearest plain-English patient reference available.

When moving up to 7.5 mg should be paused or reconsidered

There are situations where your prescriber will recommend staying at 5 mg longer, or stepping back down temporarily. These are not rare edge cases, they come up regularly in clinical practice.

Persistent nausea that has not improved after four or more weeks at 5 mg is the most common reason. Pushing the dose up before GI symptoms have settled tends to compound them rather than resolve them. A prescriber may suggest dietary adjustments (smaller meals, lower-fat foods, eating slowly) before recommending a move up.

Significant life events also matter. Illness that caused vomiting or dehydration around your recent injection days, a course of antibiotics, or a period of poor nutrition can all skew how a dose was tolerated. If the four weeks at 5 mg were disrupted, repeating them under more stable conditions can be the better call. You can find practical context on what the 5 mg step involves if you want to compare notes with your own experience.

Separately, if you are using an oral contraceptive pill, your prescriber will want to confirm you have an additional non-hormonal method in place. Tirzepatide can reduce the absorption of the pill (particularly relevant when the dose increases) and adding a barrier method for the first four weeks after each step up is the current NHS guidance. This is a safety point, not a side effect.

For people further along in the schedule, the considerations at the 10 mg step follow a similar logic, tolerance first, then response. Each step builds on the last.

How nume handles dose increases for repeat patients

At nume, no dose increase is processed automatically. When you request a repeat at a higher strength, a GPhC-registered Independent Prescriber reviews your case, your reported tolerance, any symptoms you have flagged, and your progress to date. That review happens the same day. If you are still weighing up how the earlier step from 2.5 to 5 mg compares to where you are now, that page sets out the same clinical framework your prescriber applies at each stage. If the increase is clinically appropriate, your order is dispatched the same day you place it before 12pm, arriving free with DPD the following working day.

If your prescriber has a question or wants more information before approving the step up, they will contact you directly through our aftercare team, which is available seven days a week. There are no automated approvals and no black-box algorithms. The clinical decision belongs to a named clinician. You can read more about how the service works on the about us page, or explore what the full Mounjaro treatment pathway looks like from consultation through to ongoing support. When you are ready to check whether now is the right moment for your next step, check your eligibility with our prescribers.